BioXcel Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 09 2020 - 7:00AM
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a
clinical-stage biopharmaceutical company utilizing artificial
intelligence to identify improved therapies in neuroscience and
immuno-oncology, today announced that Dr. Vimal Mehta, Founder and
Chief Executive Officer of BTI, will present at the H.C. Wainwright
22nd Annual Global Investment Conference.
Presentation Details:Event:
H.C. Wainwright 22nd Annual Global Investment
ConferenceDate: Wednesday, September 16,
2020Time: 9:30 AM ET
A live webcast of the presentation and the accompanying
presentation materials will be accessible through the Investors
section of the Company's website at www.bioxceltherapeutics.com.
Following the conference, the webcast will be archived on the
Company’s website for at least 30 days.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical
company focused on drug development that utilizes artificial
intelligence to identify improved therapies in neuroscience and
immuno-oncology. BTI's drug re-innovation approach leverages
existing approved drugs and/or clinically evaluated product
candidates together with big data and proprietary machine learning
algorithms to identify new therapeutic indices. BTI's two most
advanced clinical development programs are BXCL501, an
investigational sublingual thin film formulation in development for
acute treatment of agitation resulting from neuropsychiatric
disorders, and BXCL701, an investigational orally administered
systemic innate immunity activator in development for treatment of
a rare form of prostate cancer and for treatment of pancreatic
cancer in combination with other immuno-oncology agents. For more
information, please visit www.bioxceltherapeutics.com.
Contact Information:BioXcel Therapeutics,
Inc.www.bioxceltherapeutics.com
Investor Relations:John Grazianojgraziano@troutgroup.com
1.646.378.2942
Media:Julia Deutschjdeutsch@troutgroup.com
1.646.378.2967
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Apr 2023 to Apr 2024